![Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial | Stroke Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial | Stroke](https://www.ahajournals.org/cms/asset/1a9f3507-6f4a-41c4-8c1b-835be14ff934/strokeaha.122.042233.fig02.jpg)
Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial | Stroke
![Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases | ACS Medicinal Chemistry Letters Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases | ACS Medicinal Chemistry Letters](https://pubs.acs.org/cms/10.1021/acsmedchemlett.2c00334/asset/images/large/ml2c00334_0002.jpeg)
Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases | ACS Medicinal Chemistry Letters
![Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial | Stroke Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial | Stroke](https://www.ahajournals.org/cms/asset/06d2c2d8-fe66-45ee-950e-87daafa5c398/strokeaha.122.042233.fig04.jpg)
Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial | Stroke
Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases | ACS Medicinal Chemistry Letters
![Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases | ACS Medicinal Chemistry Letters Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases | ACS Medicinal Chemistry Letters](https://pubs.acs.org/cms/10.1021/acsmedchemlett.2c00334/asset/images/medium/ml2c00334_0008.gif)
Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases | ACS Medicinal Chemistry Letters
![Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases | ACS Medicinal Chemistry Letters Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases | ACS Medicinal Chemistry Letters](https://pubs.acs.org/cms/10.1021/acsmedchemlett.2c00334/asset/images/large/ml2c00334_0005.jpeg)
Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases | ACS Medicinal Chemistry Letters
![Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases | ACS Medicinal Chemistry Letters Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases | ACS Medicinal Chemistry Letters](https://pubs.acs.org/cms/10.1021/acsmedchemlett.2c00334/asset/images/large/ml2c00334_0003.jpeg)